share_log

8-K: GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

8-K: GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

8-K:GeoVax公布2024年第三季度财务业绩并提供业务最新情况
美股SEC公告 ·  2024/11/13 16:18

Moomoo AI 已提取核心信息

GeoVax Labs reported Q3 2024 financial results and provided updates on its vaccine programs. The company is progressing with the BARDA-funded Phase 2b trial of GEO-CM04S1 COVID-19 vaccine, expecting multiple data readouts from existing Phase 2 trials in Q4 2024. Gedeptin, its cancer therapy, is on track to enter Phase 2 for head and neck cancer in H1 2025.GeoVax's Mpox vaccine, GEO-MVA, is advancing with cGMP clinical batch production anticipated in Q4. The company reported a net loss of $5.8M for Q3 2024, compared to $8.4M in Q3 2023. Revenue from government contracts was $2.8M. R&D expenses increased to $7.4M, while G&A expenses decreased to $1.2M. Cash balance as of September 30, 2024, was $8.6M.The company strengthened its Scientific Advisory Board and is developing a continuous cell-line MVA manufacturing process. GeoVax remains focused on advancing its infectious disease vaccines and solid tumor therapies, with multiple clinical milestones expected in the coming months.
GeoVax Labs reported Q3 2024 financial results and provided updates on its vaccine programs. The company is progressing with the BARDA-funded Phase 2b trial of GEO-CM04S1 COVID-19 vaccine, expecting multiple data readouts from existing Phase 2 trials in Q4 2024. Gedeptin, its cancer therapy, is on track to enter Phase 2 for head and neck cancer in H1 2025.GeoVax's Mpox vaccine, GEO-MVA, is advancing with cGMP clinical batch production anticipated in Q4. The company reported a net loss of $5.8M for Q3 2024, compared to $8.4M in Q3 2023. Revenue from government contracts was $2.8M. R&D expenses increased to $7.4M, while G&A expenses decreased to $1.2M. Cash balance as of September 30, 2024, was $8.6M.The company strengthened its Scientific Advisory Board and is developing a continuous cell-line MVA manufacturing process. GeoVax remains focused on advancing its infectious disease vaccines and solid tumor therapies, with multiple clinical milestones expected in the coming months.
GeoVax Labs报告了2024年第三季度的财务结果,并提供了其生物-疫苗项目的更新。该公司正在推进由BARDA资助的GEO-CM04S1 COVID-19生物-疫苗的第二阶段20亿试验,预计在2024年第四季度将从现有的第二阶段试验中获得多项数据结果。其癌症治疗药物Gedeptin预计将在2025年上半年进入头颈癌的第二阶段。GeoVax的Mpox生物-疫苗GEO-MVA正在推进,预计将在第四季度进行cGMP临床生产批次。该公司报告2024年第三季度净亏损580万美金,较2023年第三季度的840万美金有所减少。来自政府合同的营业收入为280万美金。研发费用增加至740万美金,而管理和行政费用减少至120万美金。截至2024年9月30日,现金余额为860万美金。该公司加强了其科学顾问委员会,并正在开发一种连续电芯生产的MVA制造工艺。GeoVax仍然专注于推进其传染病生物-疫苗和实体肿瘤治疗,预计在未来几个月将有多个临床里程碑达成。
GeoVax Labs报告了2024年第三季度的财务结果,并提供了其生物-疫苗项目的更新。该公司正在推进由BARDA资助的GEO-CM04S1 COVID-19生物-疫苗的第二阶段20亿试验,预计在2024年第四季度将从现有的第二阶段试验中获得多项数据结果。其癌症治疗药物Gedeptin预计将在2025年上半年进入头颈癌的第二阶段。GeoVax的Mpox生物-疫苗GEO-MVA正在推进,预计将在第四季度进行cGMP临床生产批次。该公司报告2024年第三季度净亏损580万美金,较2023年第三季度的840万美金有所减少。来自政府合同的营业收入为280万美金。研发费用增加至740万美金,而管理和行政费用减少至120万美金。截至2024年9月30日,现金余额为860万美金。该公司加强了其科学顾问委员会,并正在开发一种连续电芯生产的MVA制造工艺。GeoVax仍然专注于推进其传染病生物-疫苗和实体肿瘤治疗,预计在未来几个月将有多个临床里程碑达成。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息